Advertisement

Clinical and Experimental Nephrology

, Volume 22, Issue 1, pp 35–44 | Cite as

Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia

  • Yosuke Nakayama
  • Kaoru Ueda
  • Sho-ichi Yamagishi
  • Miki Sugiyama
  • Chika Yoshida
  • Yuka Kurokawa
  • Nao Nakamura
  • Tomofumi Moriyama
  • Goh Kodama
  • Tomohisa Minezaki
  • Sakuya Ito
  • Akiko Nagata
  • Kensei Taguchi
  • Junko Yano
  • Yusuke Kaida
  • Kazutaka Shibatomi
  • Kei FukamiEmail author
Original article

Abstract

Background

Hyperkalemia is prevalent in end-stage renal disease patients, being involved in life-threatening arrhythmias. Although polystyrene sulfonate (PS) is commonly used for the treatment of hyperkalemia, direct comparison of effects between calcium and sodium PS (CPS and SPS) on mineral and bone metabolism has not yet been studied.

Methods

In a randomized and crossover design, 20 pre-dialysis patients with hyperkalemia (>5 mmol/l) received either oral CPS or SPS therapy for 4 weeks.

Results

After 4-week treatments, there was no significant difference of changes in serum potassium (K) from the baseline (ΔK) between the two groups. However, SPS significantly decreased serum calcium (Ca) and magnesium (Mg) and increased intact parathyroid hormone (iPTH) values, whereas CPS reduced iPTH. ΔiPTH was inversely correlated with ΔCa and ΔMg (r = −0.53 and r = −0.50, respectively). Furthermore, sodium (Na) and atrial natriuretic peptide (ANP) levels were significantly elevated in patients with SPS, but not with CPS, whereas ΔNa and ΔANP were significantly correlated with each other in all the patients. We also found that ΔNa and Δ(Na to chloride ratio) were positively correlated with ΔHCO3 . In artificial colon fluid, CPS increased Ca and decreased Na. Furthermore, SPS greatly reduced K, Mg, and NH3.

Conclusion

Compared with SPS, CPS may be safer for the treatment of hyperkalemia in pre-dialysis patients, because it did not induce hyperparathyroidism or volume overload.

Keywords

Chronic kidney disease Potassium Calcium Sodium Hyperkalemia Secondary hyperparathyroidism 

Notes

Acknowledgement

This work was supported, in part, by Grants-in-Aid for Welfare and Scientific Research (C) (no. 16k09637) (K.F) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Compliance with ethical standards

Conflict of interest

Dr. Fukami has received honoraria such as lecture fees from Sanwa (Sanwa Kagaku Kenkyusyo). This paper has not been published previously in whole or part.

Human rights

(with IRB approval number) All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional ethics committee at which the studies were conducted (Approval No. 13170) and with the 1964 Helsinki Declaration and its later amendments of comparable ethical standards. This trial was registered with the University Hospital Medical Information Network clinical trials database (UMIN 000021955).

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169(12):1156–62.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Torlén K, Kalantar-Zadeh K, Molnar MZ, Vashistha T, Mehrotra R. Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort. Clin J Am Soc Nephrol. 2012;7(8):1272–84.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Jarman PR, Kehely AM, Mather HM. Hyperkalaemia in diabetes: prevalence and associations. Postgrad Med J. 1995;71(839):551–2.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–60.CrossRefPubMedGoogle Scholar
  6. 6.
    Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585–92.CrossRefPubMedGoogle Scholar
  7. 7.
    Takaichi K, Takemoto F, Ubara Y, Mori Y. Analysis of factors causing hyperkalemia. Intern Med. 2007;46(12):823–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Sterns RH, Grieff M, Bernstein PL. Treatment of hyperkalemia: something old, something new. Kidney Int. 2016;89(3):546–54.CrossRefPubMedGoogle Scholar
  9. 9.
    Watson M, Abbott KC, Yuan CM. Damned if you do, damned if you don’t: potassium binding resins in hyperkalemia. Clin J Am Soc Nephrol. 2010;5(10):1723–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Tomino Y, Yamazaki T, Shou I, Tsuge T, Satake K, Takeda Y, et al. Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia–changes in serum potassium levels with or without a RAAS inhibitor. Clin Nephrol. 2007;68(6):379–85.CrossRefPubMedGoogle Scholar
  11. 11.
    Lepage L, Dufour AC, Doiron J, Handfield K, Desforges K, Bell R, et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol. 2015;10(12):2136–42.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Berlyne GM, Janabi K, Shaw AB. Dangers of resonium A in the treatment of hyperkalemia in renal failure. Lancet. 1966;1(7430):167–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Frohnert PP, Johnson WJ, Mueller GJ, Tauxe WN, McCall JT. Resin treatment of hyperkalemia. II. Clinical experience with a cation exchange resin (calcium cycle). J Lab Clin Med. 1968;71(5):840–6.PubMedGoogle Scholar
  14. 14.
    Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18.CrossRefPubMedGoogle Scholar
  15. 15.
    Block GA, Zaun D, Smits G, Persky M, Brillhart S, Nieman K, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int. 2010;78(6):578–89.CrossRefPubMedGoogle Scholar
  16. 16.
    Komaba H, Kakuta T, Fukagawa M. Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol. 2011;15(6):797–809.CrossRefPubMedGoogle Scholar
  17. 17.
    Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006;70(7):1358–66.CrossRefPubMedGoogle Scholar
  18. 18.
    Taniguchi M, Fukagawa M, Fujii N, Hamano T, Shoji T, Yokoyama K, et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial. 2013;17(2):221–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Fukagawa M, Kido R, Komaba H, Onishi Y, Yamaguchi T, Hasegawa T, et al. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. Am J Kidney Dis. 2014;63(6):979–87.CrossRefPubMedGoogle Scholar
  20. 20.
    George J, Majeed W, Mackenzie IS, Macdonald TM, Wei L. Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study. BMJ. 2013;347:f6954.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Takase H, Sugiura T, Kimura G, Ohte N, Dohi Y. Dietary sodium consumption predicts future blood pressure and incident hypertension in the Japanese normotensive general population. J Am Heart Assoc. 2015;4(8):e001959.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Manabe R, Fukami K, Ando R, Sakai K, Kusumoto T, Hazama T, et al. Effects of switching from calcium carbonate to lanthanum carbonate on bone mineral metabolism in hemodialysis patients. Ther Apher Dial. 2013;17(Suppl 1):35–40.CrossRefPubMedGoogle Scholar
  23. 23.
    Clase CM, Norman GL, Beecroft ML, Churchill DN. Albumin-corrected calcium and ionized calcium in stable haemodialysis patients. Nephrol Dial Transplant. 2000;15(11):1841–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Hynes D, Bates S, Loughman A, Klim S, French C, Kelly AM. Arteriovenous blood gas agreement in intensive care patients with varying levels of circulatory compromise: a pilot study. Crit Care Resusc. 2015;17(4):253–6.PubMedGoogle Scholar
  25. 25.
    Yamada T, Alpers D, Laine L, Owyang C, Powell D. Approach to the patient with diarrhea. Textb Gastroenterol. 2003;1:858–64.Google Scholar
  26. 26.
    Evans BM, Jones NC, Milne MD, Yellowlees H. Ion-exchange resins in the treatment of anuria. Lancet. 1953;265(6790):791–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Li M, Jiang J, Yue L. Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7. J Gen Physiol. 2006;127(5):525–37.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Kumar R, Thompson JR. The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol. 2011;22(2):216–24.CrossRefPubMedGoogle Scholar
  29. 29.
    Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366(6455):575–80.CrossRefPubMedGoogle Scholar
  30. 30.
    Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev. 2001;81(1):239–97.CrossRefPubMedGoogle Scholar
  31. 31.
    Shoback DM, Thatcher JG, Brown EM. Interaction of extracellular calcium and magnesium in the regulation of cytosolic calcium and PTH release in dispersed bovine parathyroid cells. Mol Cell Endocrinol. 1984;38(2–3):179–86.CrossRefPubMedGoogle Scholar
  32. 32.
    Sakaguchi Y, Shoji T, Hayashi T, Suzuki A, Shimizu M, Mitsumoto K, et al. Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease. Diabetes Care. 2012;35(7):1591–7.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int. 2014;85(1):174–81.CrossRefPubMedGoogle Scholar
  34. 34.
    Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;341:c3691.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Jadoul M, Karaboyas A, Goodkin DA, Tentori F, Li Y, Labriola L, et al. Potassium-binding resins: associations with serum chemistries and interdialytic weight gain in hemodialysis patients. Am J Nephrol. 2014;39(3):252–9.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Powell DW, Berschneider HM, Lawson LD, Martens H. Regulation of water and ion movement in intestine. Ciba Found Symp. 1985;112:14–33.PubMedGoogle Scholar
  37. 37.
    Kamel KS, Schreiber M. Asking the question again: are cation exchange resins effective for the treatment of hyperkalemia? Nephrol Dial Transplant. 2012;27(12):4294–7.CrossRefPubMedGoogle Scholar
  38. 38.
    van de Strihou CY, Dieu JP. Potassium deficiency acidosis in the dog: effect of sodium and potassium balance on renal response to a chronic acid load. Kidney Int. 1977;11(5):335–47.CrossRefGoogle Scholar
  39. 39.
    Lindner G, Schwarz C, Grüssing H, Kneidinger N, Fazekas A, Funk GC. Rising serum sodium levels are associated with a concurrent development of metabolic alkalosis in critically ill patients. Intensive Care Med. 2013;39(3):399–405.CrossRefPubMedGoogle Scholar
  40. 40.
    Luke RG, Galla JH. It is chloride depletion alkalosis, not contraction alkalosis. J Am Soc Nephrol. 2012;23(2):204–7.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Seifter JL. Integration of acid-base and electrolyte disorders. N Engl J Med. 2014;371(19):1821–31.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2017

Authors and Affiliations

  • Yosuke Nakayama
    • 1
  • Kaoru Ueda
    • 1
    • 2
  • Sho-ichi Yamagishi
    • 3
  • Miki Sugiyama
    • 1
  • Chika Yoshida
    • 1
  • Yuka Kurokawa
    • 1
  • Nao Nakamura
    • 1
  • Tomofumi Moriyama
    • 1
  • Goh Kodama
    • 1
  • Tomohisa Minezaki
    • 1
  • Sakuya Ito
    • 1
  • Akiko Nagata
    • 1
  • Kensei Taguchi
    • 1
  • Junko Yano
    • 1
  • Yusuke Kaida
    • 1
  • Kazutaka Shibatomi
    • 2
  • Kei Fukami
    • 1
    Email author
  1. 1.Division of Nephrology, Department of MedicineKurume University School of MedicineKurumeJapan
  2. 2.Department of Rheumatology and NephrologyOita Prefectural HospitalOitaJapan
  3. 3.Department of Pathophysiology and Therapeutics of Diabetic Vascular ComplicationsKurume University School of MedicineKurumeJapan

Personalised recommendations